Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre Evrard

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Pharmacogenetics and Genomics|September 22, 2007
Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulationCédric Mercier, Caroline Raynal, Laetitia Dahan, et al.
Antibiotics (Basel, Switzerland)|November 13, 2020
Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care UnitNicolas Perin, Claire Roger, Grégory Marin, et al.
Pharmaceutics|April 23, 2022
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual SuspectsFanny Leenhardt, Frédéric Fiteni, Ludovic Gauthier, et al.
Cells|July 12, 2020
The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X ReceptorNicolas Creusot, Matthieu Gassiot, Elina Alaterre, et al.
Brain, Behavior, & Immunity - Health|December 9, 2024
Genetic association of the kynurenine pathway to suicidal behaviorRabah Tamimou, Christine Montout, Thibault Mura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapiesJoseph Ciccolini, Laetitia Dahan, Nicolas André, et al.
Cancers|July 24, 2021
PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1Alice Matheux, Matthieu Gassiot, Gaëlle Fromont, et al.
Journal of Hepatology|May 7, 2014
Characterization of a novel PXR isoform with potential dominant-negative propertiesCyril Breuker, Chris Planque, Fatemeh Rajabi, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 24, 2024
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patientsAlicja Puszkiel, Florence Dalenc, Naïma Tafzi, et al.
Clinical Pharmacology and Therapeutics|February 21, 2019
Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS StudyAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Pharmacogenetics and Genomics|September 22, 2007
Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulationCédric Mercier, Caroline Raynal, Laetitia Dahan, et al.
Antibiotics (Basel, Switzerland)|November 13, 2020
Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care UnitNicolas Perin, Claire Roger, Grégory Marin, et al.
Pharmaceutics|April 23, 2022
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual SuspectsFanny Leenhardt, Frédéric Fiteni, Ludovic Gauthier, et al.
Cells|July 12, 2020
The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X ReceptorNicolas Creusot, Matthieu Gassiot, Elina Alaterre, et al.
Brain, Behavior, & Immunity - Health|December 9, 2024
Genetic association of the kynurenine pathway to suicidal behaviorRabah Tamimou, Christine Montout, Thibault Mura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapiesJoseph Ciccolini, Laetitia Dahan, Nicolas André, et al.
Cancers|July 24, 2021
PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1Alice Matheux, Matthieu Gassiot, Gaëlle Fromont, et al.
Journal of Hepatology|May 7, 2014
Characterization of a novel PXR isoform with potential dominant-negative propertiesCyril Breuker, Chris Planque, Fatemeh Rajabi, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 24, 2024
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patientsAlicja Puszkiel, Florence Dalenc, Naïma Tafzi, et al.
Clinical Pharmacology and Therapeutics|February 21, 2019
Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS StudyAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Pageof 7